Immunotherapy News and Research

Latest Immunotherapy News and Research

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

16 Jun 2014

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it has been granted Certificate of Good Manufacturing Practice (GMP) compliance for its cell therapy manufacturing facility in Besançon, France.

12 Jun 2014

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

A landmark survey of more than 700 specialists provides crucial real-world insight into the treatments most oncologists choose for lung cancer patients whose tumour has been incompletely resected, an expert from the European Society for Medical Oncology (ESMO) says.

11 Jun 2014

Knowing summer allergies

As if a runny nose and red eyes weren't enough to ruin your warm weather look, summer allergies can gift you with even more than you've bargained for this year. In fact, some unusual symptoms can leave you looking like you lost a round in a boxing ring.

11 Jun 2014

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced today that it has initiated the Phase III trial of DCVax-L in Germany.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Advances in understanding of genetics of CAD lead to more therapeutic targets

Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

9 Jun 2014

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax, a cancer immunotherapeutic "vaccine" that specifically targets the tumor blood vessels (endothelium).

9 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

Dendreon shareholders call for annual elections to increase board independence and accountability

Eighty-four percent (84%) of votes cast by shareholders at Dendreon voted in favor of a proxy proposal calling for annual election of board members, a strategy - which if enacted - would increase board independence and accountability.

6 Jun 2014

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of LV305, an immuno-oncology investigational agent from the company's DCVexTM lentiviral vector platform.

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Cellectis, a leader of engineered CART cell therapies, and Thermo Fisher Scientific announced today that they have entered into a series of agreements covering the uses of TAL nucleases under the brand name TALEN™.

5 Jun 2014

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

A physician-scientist who developed a personalized immunotherapy for leukemia using patients' own T cells is the recipient of the 2014 Taubman Prize for Excellence in Translational Medical Science, awarded by the A. Alfred Taubman Medical Research Institute at the University of Michigan Medical School.

4 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

Yoga can't be considered routine intervention for patients with asthma

Yoga has long been promoted as a method for improving physical and mental well-being. And although yoga is often suggested to asthma sufferers to help alleviate symptoms, a new study found little evidence that yoga will improve symptoms.

4 Jun 2014

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Researchers at the University of Illinois at Chicago are conducting a clinical trial to evaluate a new, three-drug combination therapy for advanced pancreatic cancer.

4 Jun 2014

Immunotherapy News and Research

Latest Immunotherapy News and Research

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

TxCell receives Certificate of GMP compliance for cell therapy manufacturing facility in France

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Knowing summer allergies

Northwest Biotherapeutics initiates Phase III trial of DCVax-L in Germany

Celsion signs definitive asset purchase agreement to acquire EGEN

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Advances in understanding of genetics of CAD lead to more therapeutic targets

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Research roundup: Funding for safety-net hospitals; insurance competition

Dendreon shareholders call for annual elections to increase board independence and accountability

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Leukemia researcher wins 2014 Taubman Prize for Excellence in Translational Medical Science

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Yoga can't be considered routine intervention for patients with asthma

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in